Asthma patients who rely on blue ‘reliever’ inhalers are being urged to contact their GP following updated medical guidance warning that overuse could worsen their condition. The alert comes after new recommendations from the National Institute for Health and Care Excellence (NICE), which advise moving away from sole reliance on short-acting inhalers such as salbutamol, commonly found in brands like Ventolin.
For decades, these blue inhalers – known as short-acting beta2 agonists (SABAs) – have been widely used to provide quick relief from asthma symptoms by relaxing airway muscles and easing breathing during attacks. However, experts now say they may only treat symptoms temporarily, while failing to address the underlying inflammation.
NICE has warned that relying too heavily on these inhalers ‘masks the problem without fixing it’ and cautions that overuse is linked to a higher risk of asthma attacks, hospital admissions and even death. Recent data suggests nearly half (48%) of blue inhaler users in England were prescribed more than two inhalers between 2024 and 2025 – a level specialists consider concerning.
MORE ON HEALTH
Dr Amina Al-Yassin, a GP and clinical lead for children and young people’s services at Brent Integrated Care Partnership, said: “They make people feel better, but only briefly. We now know that over time, they are likely to make asthma worse. Seeing a blue inhaler used alone is now a dangerous sign to me.”
Under the updated guidance, patients aged 12 and over who are newly diagnosed or require additional treatment are being advised to switch to combination inhalers, writes Elaine Blackburne from Wales Online. These combine an inhaled steroid with a long-acting beta2 agonist (LABA), typically formoterol, to both relieve symptoms and treat the inflammation that causes them.
Two treatment approaches are now being promoted:
- Anti-inflammatory reliever (AIR): For people who only experience asthma symptoms less than twice a month, during certain times of the year, such as pollen season, when around pets, or during exercise
- Maintenance and reliever therapy (MART): For people who have asthma symptoms more regularly
Professor Ewan Maule, director of medicines and pharmacy at North East and North Cumbria Integrated Care Board, said: “For over 50 years, the blue inhaler has been prescribed for people with asthma, providing quick relief for breathing difficulties. We now know that asthma is not just about keeping the airways open, it’s also about controlling the inflammation, or swelling, that causes the symptoms in the first place.
“By upgrading to a combined treatment inhaler patients not only get the relief they need but also benefit from treatment that treats the root cause of their asthma. This can lead to fewer flare-ups, fewer hospital visits, and better long-term lung health.”
Health officials are now encouraging anyone who regularly uses a blue inhaler to review their treatment plan with their GP. Claire Adams, respiratory clinical lead at the integrated care board, said: “Having the right plan and using the right inhaler, in the right way, can make all the difference in managing asthma effectively.
“The new combination inhalers offer more protection and better control, helping people to live well and breathe more easily. Reviewing your asthma action plan with a healthcare professional will ensure you understand how to use the right inhaler correctly and get the best protection for your lungs, helping you to live symptom-free!”
Patients are advised to contact their GP practice for more details and to discuss whether switching to a combination inhaler could improve their asthma control.
MORE USEFUL INFORMATION